Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Snap On Incorporated (SNA) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Snap On Incorporated — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.99 (market cap $4.49B), while Snap On Incorporated trades at $400.72 (market cap $21.17B). The key difference: Snap On Incorporated is far larger — about 4.7× ACADIA Pharmaceuticals Inc.'s market cap, and Snap On Incorporated pays a 2.39% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | SNA | |
|---|---|---|
Market Cap | $4.49B | $21.17B |
Sector | Health | Technology |
52-Week High | $28.06 | $413.62 |
52-Week Low | $20.06 | $313.01 |
Enterprise Value | $3.69B | $20.69B |
Dividend Yield | — | 2.39% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
Snap-on Incorporated (SNA) trades at $413.62, up 0.37% with a bullish technical outlook supported by moving averages. The company maintains strong profitability with a 19.6% net income margin and recently beat Q4 2025 earnings. Recent acquisitions like Diesel Laptops for $100 million demonstrate strategic growth initiatives. Analyst consensus is positive with 65% buy ratings and a $407.50 price target.
SNA presents a stable investment with consistent dividend payments and share repurchases, though Q1 2026 earnings miss and elevated valuation ratios pose near-term risks. The stock's technical overbought condition suggests potential consolidation before further upside. Long-term growth depends on successful integration of acquisitions and maintaining premium margins in the competitive tools market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Snap On Incorporated
Snap-on Incorporated is a leading global innovator, manufacturer, and marketer of tools, equipment, diagnostics, repair information, and systems solutions for professional users. Its products are widely used in vehicle service and repair, as well as in other demanding industrial environments. The company is best known for its premium tool brand, often sold through a network of franchised mobile stores, and is a primary supplier to technicians in the transportation industry.
Read more on SNA →
